LNP platforms
Lipid nanoparticles (LNPs) act as advanced nanocarriers for nucleic acid delivery. They help protect the active payload from systemic degradation and deliver it to the intended site of action. By avoiding degradation and increasing delivery of their payload to the cytosol, LNPs enable more efficient & more effective nucleic acid therapeutics.
Customized LNP (cLNP) development
We believe that customized LNPs are critical enablers in advancing nucleic acid-based products to new levels of prophylactic and therapeutic utility. etherna has built expertise and implemented a suite of experimental approaches to customize LNPs for specific therapeutic applications. Additionally, etherna has advanced proprietary ionizable lipid libraries with different properties that we use to develop cLNPs. Our cLNP development capabilities are evidenced by our innovative and proprietary LNP platforms. We tailored those for specific routes of administration allowing better targeted biodistribution with an improved safety profile. Read below about some examples of cLNPs we have developed. With our expertise, suite of experimental tools, and proprietary ionizable lipid libraries, we support the development of LNPs customized for a specific payload and application.
IM delivery
Infectious diseases
Prophylactic vaccine
- Immune-stimulatory LNPs optimized for intramuscular admin and maximized antibody responses
- Well-tolerated formulations, with very low local reactogenicity and a similar safety profile as clinically validated benchmarks
IT delivery
Intratumoral immunomodulation Immuno-oncology
- Inducing systemic T cell antitumor immunity by local intratumoral injection
- Maximized local mRNA expression with reduced off-target expression in the liver
IV delivery
Liver diseases, secreted factors & gene editing
- Superior liver expression after repeated dosing compared to clinically validated benchmarks
- Well-tolerated formulations, without liver damage, based on ALT/AST assessments
IV delivery
Tolerizing vaccine for autoimmune diseases
- Inducing immune tolerance against auto-antigen to treat autoimmune diseases
- Low-inflammatory, immune-silent LNP optimized for intravenous admin
IV delivery
Genetic diseases &
gene editing
- LNPs optimized to de-target the liver and robust expression in hematopoietic stem cells (HSC)
IV delivery
Immuno-oncology &
autoimmune diseases
- T-LNP are optimized for ex vivo/in vivo T-cell reprogramming to treat tumors or autoimmune diseases
Comprehensive
Our different families of LNP formulations cover different therapeutic applications, such as prophylactic and cancer vaccines, gene therapy, protein replacement, etc.
Customizable
With our expertise, suite of experimental tools, and proprietary ionizable lipid libraries, we support the development of LNPs customized for a specific payload and application.
World Class facilities
Our world-class LNP manufacturing facilities in Ghent & Niel, Belgium, support the production of LNPs for any preclinical project and scale up the LNP production to a GMP-ready stage.
Contact us with any queries or for pricing information.